Coverage / ABT / Trade Card

ABT

Abbott Laboratories

OPPORTUNISTIC BUY Analysis generated 2026-10-04 Market data as of 2026-11-12 Market data 3 days old USD 107.25 Healthcare - Medical - DevicesAWAIT ENTRY
ACTIONABLEMethodology gates passed
62

Position levels

Currenttoday
USD 107.25
Buy <=wait / entry
USD 91.33
Trim >=take some off
USD 110.00
Thesis breakA confirmed cyber incident materially disrupting device shipments, a downgrade t...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case30%100 / 10030.0
Base case49%62 / 10030.4
Bear case21%10 / 1002.1
Weighted conviction62 / 100 - OPPORTUNISTIC BUY

Top risks

  • M&A activity: $23 billion Exact Sciences acquisition closed March 2026 adding Cologuard and Oncotype DX to diagnostics portfolio
  • Earnings/guidance changes: Q2 adjusted EPS $1.31 beat, raised full-year 2026 adjusted EPS guidance to $5.45-$5.60 from prior $5.38-$5.58
  • Strategic trial progress: Completed enrollment in TECTONIC U.S. pivotal trial for Coronary Intravascular Lithotripsy
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n